ArticleInfection prevention in practice2022
Molecular and genetic characterization of emerging carbapenemase-producing
Article in Infection prevention in practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Complete genome of multiply antibiotic resistant ST10Microbiology spectrum · 2026Article
- Comparative Analysis of Biofilm Formation and Antibiotic Resistance in Five ESKAPE Pathogen Species from a Tertiary Hospital in Bangladesh.Antibiotics (Basel, Switzerland) · 2025Article
- Superbug Surge-A Tale of Seven-Year Battle Against Escalating Antimicrobial Resistance in North India.Current microbiology · 2025Article
- Isolation and characterization of Acinetobacter baumannii from environmental waters in Dhaka City, Bangladesh.BMC microbiology · 2025Article
- Impact of Antimicrobial Stewardship and Infection Prevention and Control Programmes on Antibiotic Usage andInfection and drug resistance · 2025Article
- Colonisation of hospital surfaces from low- and middle-income countries by extended spectrum β-lactamase- and carbapenemase-producing bacteria.Nature communications · 2024Article
- Multidrug-resistantHeliyon · 2023Article
- Multidrug-Resistant and Extensively Drug-ResistantMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenemase-producing multidrug-resistant (MDR) Aim: To investigate the detailed molecular epidemiology of carbapenem-resistant Methods: A set of 49 clinical Findings: Clinical Conclusion: Widespread dissemination of MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.